Echelon Wealth Partners Reaffirms Buy Rating for Patient Home Monitoring (CVE:PTQ)

Echelon Wealth Partners reiterated their buy rating on shares of Patient Home Monitoring (CVE:PTQ) in a research report report published on Tuesday morning, Zacks.com reports.

Shares of PTQ stock traded up C$0.02 on Tuesday, hitting C$0.97. The stock had a trading volume of 172,165 shares, compared to its average volume of 122,377. The company has a debt-to-equity ratio of 161.32, a quick ratio of 1.05 and a current ratio of 1.42. Patient Home Monitoring has a 52-week low of C$0.66 and a 52-week high of C$1.19.

Patient Home Monitoring Company Profile

Protech Home Medical Corp. provides and rents in-home monitoring equipment and services for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; INR self-testing equipment; BiPAP and CPAP machines, oxygen concentrators, and ventilators; oxygen therapy; sleep apnea and PAP treatment equipment; and home ventilator equipment.

Featured Story: Stocks at 52 Week High

Receive News & Ratings for Patient Home Monitoring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patient Home Monitoring and related companies with MarketBeat.com's FREE daily email newsletter.